Sector News

Bone Therapeutics showcases allogeneic cell therapy data

October 24, 2020
Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

The data demonstrated a 90% successful lumbar vertebrae fusion rate at 24 months, with patients also continuing to experience clinical improvements in function and pain.

The results comes from a multi-centre, open-label phase IIa study designed to evaluate the safety and efficacy of Allob.

The main endpoints of the 24-month follow-up included safety and radiological assessments to evaluate vertebrae fusions and clinical assessments to evaluate improvement in patients’ functional disability, as well as reduction in back and leg pain.

Spinal fusion procedures are performed to relieve pain and improve patient’s daily function for a broad spectrum of degenerative spine disorders.

This consists of bridging two or more vertebrae with the use of a cage and graft material for fusing an unstable portion of the spine and immobilising a painful intervertebral motion segment.

“These studies provide promising clinical evidence for the potential of Bone Therapeutics’ unique allogeneic cell therapy platform to address high unmet medical needs in orthopaedics and bone related disorders,” said Miguel Forte, chief executive officer of Bone Therapeutics.

“We will now hold discussions with global regulators and our partners to explore a variety of options for the next stages of clinical development for Allob in different orthopaedic indications, while pursuing the phase IIb study of Allob in difficult tibial fractures.

“In addition, the clinical results provide further evidence for the expansion of ALLOB and our platform of differentiated MSCs to other indications,” he added.

By Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).